Breast Cancer: Basic and Clinical Research

Breast Cancer: Basic and Clinical Research is a peer reviewed, fully open access oncology journal that carries laboratory and clinical work on breast cancer, and it is published by SAGE Publishing.《乳腺癌基础与临床研究》是一份同行评审的完全开放获取肿瘤学期刊，刊载乳腺癌在基础层面与临床层面的研究工作，由 SAGE 出版集团发行。

The title was started in 2008 in Auckland, New Zealand, and in the 2025 journal citation report it holds an impact factor of 2.2 in the oncology category, where it stands in the third quartile.该刊 2008 年在新西兰奥克兰创刊，在 2025 年版期刊引证报告中列于肿瘤学类目，影响因子为 2.2，在该类目中位处第三区。

Scope

• The stated remit reaches across every part of breast cancer research and treatment, from work at the molecule to the care of the woman who has the disease. The phrase basic and clinical has stood in the title since the first volume.该刊自述的收稿范围横跨乳腺癌研究与治疗的各个环节，自分子层面的基础研究直到患者的实际照护。题名中的基础与临床自第一卷起未曾改变。

• Molecular subtypes are treated as a subject in their own right, and papers are admitted that sort tumours into groups such as luminal, HER2 enriched and triple negative disease.分子分型在该刊自成一门主题，凡是把肿瘤划入管腔型、HER2 富集型与三阴性等类别的论文都在收载之列。

• Pathobiology is part of the remit, and the journal carries work on how a normal cell turns malignant and on how a tumour then changes.病理生物学属于收稿范围，该刊刊载正常细胞如何恶性变、肿瘤此后又如何变化的研究。

• Metastasis is named among the themes, and the journal takes work on the routes by which tumour cells leave the breast and seed distant organs.转移被列为主题之一，该刊收载肿瘤细胞如何脱离乳腺、又如何在远处器官落脚播散开的路径研究。

• Genetics is covered, and the journal admits work on inherited risk and on the mutations that drive tumour growth.遗传学在收稿之列，该刊收载遗传风险与推动肿瘤生长之突变两个方向的研究。

• Epigenetic regulation is treated, and the journal carries work on how methylation and chromatin state switch genes on and off in breast tissue.表观遗传调控得到处理，该刊刊载甲基化与染色质状态如何开关乳腺组织中基因的研究。

• Mammary gland biology is named, and the journal takes work on the normal development of the breast and on the stem cells that line it.乳腺生物学被点名，该刊收载乳腺的正常发育与周期变化，以及排列其间的干细胞研究。

• Experimental models form another theme, and the journal carries work built on cell lines, on organoids, on xenografts and on genetically engineered animals.实验模型构成另一主题，该刊刊载基于细胞系、类器官、异种移植与基因工程动物开展的工作。

• Prevention is part of the remit, and the journal admits work on chemoprevention, on the prediction of risk and on the measures that lower a woman's chances before any tumour appears.预防属于收稿范围，该刊收载化学预防、风险预测以及在肿瘤出现之前降低女性患病可能的各种措施。

• Detection is covered, and the journal takes work on screening, on imaging of the breast and on the markers that give warning of a tumour.检测在收稿之列，该刊收载筛查方案、乳腺影像以及能够预警肿瘤的标志物研究。

• Therapy is a large part of the remit, and the journal carries work on chemotherapy, on endocrine treatment, on targeted agents and on immunotherapy in the disease.治疗是收稿范围的重要部分，该刊刊载化疗、内分泌治疗、靶向药物与免疫治疗在该病中的研究，各类疗法之间的比较同样在列。

• Clinical intervention is treated, and the journal admits work on surgery, on radiotherapy and on the supportive care given around both.临床干预得到处理，该刊收载手术、放射治疗、围手术期管理以及两者前后给予的支持性照护。

• Epidemiology is named among the themes, and the journal takes work on the occurrence of the disease in populations and on the numbers that describe it.流行病学被列为主题之一，该刊收载该病在人群中的发生情况、地区间的差异以及描述它的各项统计数字。

• Prognostic and predictive markers are part of the remit, and the journal carries work that sorts patients into groups for the sake of treatment choice.预后标志物与预测标志物属于收稿范围，该刊刊载为选择治疗方案而对患者分组的探讨，也刊载这些标志物在队列中的检验。

• Clinical trials are named among the themes, and the journal carries work on how a new agent is weighed against the standard treatment in the disease.临床试验被列为主题之一，该刊刊载新药在乳腺癌中与标准治疗相互比较的研究。

History

• The journal was founded in 2008 in Auckland, New Zealand by Libertas Academica, an independent scholarly publisher working out of that city.该刊由总部设在奥克兰的独立学术出版商 Libertas Academica 于 2008 年在新西兰奥克兰创办。

• Its first volume belongs to the year of that founding, and the volume numbering has run without a break since, reaching volume 20 in 2026.创刊当年即出版第一卷，此后卷号未曾中断，2026 年已出至第 20 卷。

• The catalogue record of the National Library of Medicine keeps both imprints, the original one in Auckland under Libertas Academica and the current one in Thousand Oaks, California under SAGE Publications.美国国立医学图书馆的编目记录同时保留两段出版项，其一为奥克兰 Libertas Academica，其二为加利福尼亚州千橡市 SAGE Publications。

• Publication passed to SAGE in 2016, and the journal has since been produced from Thousand Oaks, California.该刊自 2016 年起转入 SAGE 出版，此后一直在加利福尼亚州千橡市印制。

• Articles are published continuously and carry no issue numbers, one volume appearing for each calendar year with the articles inside it numbered in a single sequence.文章采用连续出版方式且不编期号，每个自然年出版一卷，卷内文章按单一顺序连续编号。

• Under SAGE the pattern has held without exception, running from volume 10 in 2016 through volume 19 in 2025.在 SAGE 旗下这一格局未曾间断，自 2016 年的第 10 卷排到 2025 年的第 19 卷。

• The year 2015 carried a volume of its own together with two supplements, numbered 9s1 and 9s2, which the publisher issued beside the main sequence.2015 年除本年一卷之外另有两种增刊，编号为 9s1 与 9s2，由出版方与正卷一并推出。

• Output stays modest and steady, with the journal citation report counting 26 articles for 2025 and a similar number in most other years of the SAGE period.刊量不大而稳定，期刊引证报告为 2025 年记 26 篇文章，SAGE 期间多数年份与之相近。

• Medline coverage reaches back to volume 4 in 2010, and the full text of the journal is held in PubMed Central.Medline 的收录可回溯至 2010 年的第 4 卷，期刊全文由 PubMed Central 收录。

• The journal is listed in the Emerging Sources Citation Index, and in the 2025 edition of the journal citation report it sits 228th of 333 titles in oncology.该刊被列入新引源索引，在 2025 年版期刊引证报告中于肿瘤学类目的 333 种期刊里列第 228 位。

• Scopus, EBSCO and ProQuest hold the journal as well, and it is listed among open access titles in the Directory of Open Access Journals.Scopus、EBSCO 与 ProQuest 亦收录该刊，该刊同时列于开放获取期刊目录（DOAJ）之中。

• Its impact factor has risen across three years, from 1.8 in 2023 to 1.9 in 2024 and 2.2 in 2025, with a five year figure of 2.5.该刊影响因子三年间上行，2023 年为 1.8，2024 年为 1.9，2025 年为 2.2，五年指标为 2.5。

• The citation record stands at 753 citations and the half life of the papers reaches 7.4 years, and a single international number covers both the printed and the electronic editions.该刊的引用记录为 753 次，论文引用半衰期达 7.4 年，印刷版与电子版共用同一个国际标准刊号。

• In the catalogue the journal carries the abbreviated form Breast Cancer (Auckl), which keeps the New Zealand origin of the title in view.在编目记录中，该刊的缩写形式是 Breast Cancer (Auckl)，把该刊的新西兰渊源留在题面之上。

Editors

• Those in charge are led by an editor in chief, Goberdhan P. Dimri, who works at the George Washington University Medical Center in Washington, District of Columbia.该刊由主编（Goberdhan P. Dimri）掌舵，他供职于华盛顿特区的乔治华盛顿大学医学中心。

• Statistical appraisal of submitted papers is shared by two biostatistical editors, and the first of them is Xueliang (Jeff) Pan of the Department of Biomedical Informatics at The Ohio State University.稿件的统计评审由两位统计编辑分担，其中一位是俄亥俄州立大学生物医学信息学系的（Xueliang (Jeff) Pan）。

• The other biostatistical editor is Muni Rubens, who holds the post alongside a position at the Miami Cancer Institute.另一位统计编辑是（Muni Rubens），他兼任迈阿密癌症中心的职务。

• The editorial board draws members from several countries, with people based in Italy, Turkey, Bolivia, the United States, China and Finland, and the spread matches a journal that publishes work on the disease from every inhabited continent.编委成员来自多个国家，分驻意大利、土耳其、玻利维亚、美国、中国与芬兰，这样的国籍分布与该刊在各大洲的覆盖面相合。

• Every submitted paper is handled by academic editors who work in the fields the journal covers, from molecular biology through to clinical practice.每份投稿都由学术编辑处理，这些编辑来自该刊所覆盖的各个领域，从分子生物学一直到临床实践。

• Manuscripts are submitted through the ScholarOne Manuscripts system, and the submission address for the journal is the one kept by that service.稿件经 ScholarOne Manuscripts 系统提交，该刊的投稿地址由该服务提供。

• The journal charges an article processing charge of 3000 US dollars, payable on acceptance, and asks for no page charge beyond that sum.该刊收取 3000 美元的文章处理费，于稿件录用时支付，除此之外不收版面费。

• That charge sits against an open access model, under which the published article is free to read and every article in the journal is available without a subscription.该费用对应开放获取模式，发表的文章可免费阅读，期刊全部文章均无需订阅即可获取。

• The publisher's records put the gold open access share of the journal at the whole of it, and no article in the run sits behind a paywall.出版方的记录显示该刊的金色开放获取比例覆盖全部卷次，没有一篇文章被挡在付费墙之后。

• Authors are asked to work within the codes of the Committee on Publication Ethics, and the journal itself belongs to that body.该刊要求作者遵循出版伦理委员会的准则，该刊本身也是该组织的成员。

• Articles are written in English, and the journal takes submissions from anywhere in the world.文章以英文写成，该刊接收来自世界各地的投稿。

• In the 2025 journal citation report the journal holds a journal citation indicator of 0.42 and sits at the 31.7 percentile of its category.在 2025 年版期刊引证报告中，该刊的期刊引证指标为 0.42，在所属类目中处于 31.7 百分位。

• Similarity checking is run on the manuscripts of the journal, and the publisher's deposit record shows that step in place for the whole archive.该刊稿件接受查重，出版方的存档记录显示这一步在全部馆藏卷次中都已落实。